Clinigen Group plc Director/PDMR Shareholding (8881M)
October 19 2016 - 3:00AM
UK Regulatory
TIDMCLIN
RNS Number : 8881M
Clinigen Group plc
19 October 2016
19 October 2016
Director's Share Dealing
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the
global pharmaceutical and services group, announces that it was
notified on 18 October 2016 that the following transactions took
place on 18 October 2016.
Shaun Chilton, the Group Chief Executive Officer-designate, has
exercised a total of 206,389 nil cost options over ordinary shares
of 0.1 pence each in the Company. The options have been satisfied
by shares from the Clinigen Group Employment Benefit Trust. He has
subsequently sold 97,246 ordinary shares of 0.1 pence each in the
Company at a price of 750 pence per share in order to meet the
expected tax obligations.
Following these transactions, Mr Chilton's total beneficial
interest in the Company is 412,943 ordinary shares representing
approximately 0.36 per cent of the current issued share
capital.
Separately, Peter George, the Group Chief Executive Officer,
sold 2,200,000 ordinary shares of 0.1 pence each in the Company at
a price of 750 pence per share.
Following these transactions, Mr George's total beneficial
interest in the Company is 3,357,242 ordinary shares, representing
approximately 2.93 per cent of the current issued share
capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging
managerial responsibilities/person
closely associated
---- ------------------------------------------------------------------
a) Name Shaun Chilton
---- ---------------------- ------------------------------------------
2 Reason for the notification
---- ------------------------------------------------------------------
a) Position/status Group Chief Executive Officer-designate
---- ---------------------- ------------------------------------------
b) Initial Initial Notification
notification
/Amendment
---- ---------------------- ------------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform,
auctioneer or auction monitor
---- ------------------------------------------------------------------
a) Name Clinigen Group plc
---- ---------------------- ------------------------------------------
b) Legal Entity N/A
Identifier
---- ---------------------- ------------------------------------------
4 Details of the transaction(s): section
to be repeated for (i) each type
of instrument; (ii) each type of
transaction; (iii) each date; and
(iv) each place where transactions
have been conducted
---- ------------------------------------------------------------------
a) Description Ordinary shares of 0.1 pence
of the financial each
instrument, GB00B89J2419
type of
instrument
Identification
code
---- ---------------------- ------------------------------------------
b) Nature of 1. The exercise of 206,389
the transaction options over ordinary shares
in the Company following
the vesting of an award
granted under the Long Term
Incentive Plan.
2. The sale of 97,246 ordinary
shares in the Company made
in order to meet expected
tax obligations arising
from the transaction described
in 1.
---- ---------------------- ------------------------------------------
c) Currency GBP
---- ---------------------- ------------------------------------------
d) Price(s) Price(s) Volume(s)
and volume(s)
---- ---------------------- -------------------- --------------------
750p 97,246
--------------------------- -------------------- --------------------
e) Aggregated 97,246
information
- Aggregated 750p
volume
- Price GBP729,345
- Aggregated
total
--------------------------- ------------------------------------------
f) Date of 18 October 2016
the transaction
---- ---------------------- ------------------------------------------
g) Place of London Stock Exchange, AIM
the transaction
---- ---------------------- ------------------------------------------
1 Details of the person discharging
managerial responsibilities/person
closely associated
---- --------------------------------------------------------
a) Name Peter George
---- ---------------------- --------------------------------
2 Reason for the notification
---- --------------------------------------------------------
a) Position/status Group Chief Executive Officer
---- ---------------------- --------------------------------
b) Initial Initial Notification
notification
/Amendment
---- ---------------------- --------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform,
auctioneer or auction monitor
---- --------------------------------------------------------
a) Name Clinigen Group plc
---- ---------------------- --------------------------------
b) Legal Entity N/A
Identifier
---- ---------------------- --------------------------------
4 Details of the transaction(s): section
to be repeated for (i) each type
of instrument; (ii) each type of
transaction; (iii) each date; and
(iv) each place where transactions
have been conducted
---- --------------------------------------------------------
a) Description Ordinary shares of 0.1 pence
of the financial each
instrument, GB00B89J2419
type of
instrument
Identification
code
---- ---------------------- --------------------------------
b) Nature of Sale of shares
the transaction
---- ---------------------- --------------------------------
c) Currency GBP
---- ---------------------- --------------------------------
d) Price(s) Price(s) Volume(s)
and volume(s)
---- ---------------------- --------------- ---------------
750p 2,200,000
--------------------------- --------------- ---------------
e) Aggregated 2,200,000
information
- Aggregated 750p
volume
- Price GBP16,500,000
- Aggregated
total
--------------------------- --------------------------------
f) Date of 18 October 2016
the transaction
---- ---------------------- --------------------------------
g) Place of London Stock Exchange, AIM
the transaction
---- ---------------------- --------------------------------
-Ends-
Contact Details
Clinigen Group plc Tel: +44 (0) 1283
495 010
Peter George, Group Chief Executive
Officer
Shaun Chilton, Group Chief
Executive Officer - designate
Martin Abell, Group Chief Financial
Officer
Numis Securities Limited Tel: +44 (0) 20
7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Tom Ballard
(Corporate Broking)
Peel Hunt LLP - Joint Broker Tel: +44 (0) 20
7418 8900
James Steel / Dr Christopher
Golden
Instinctif Partners (media Tel: +44 (0) 20
relations) 7457 2020
Melanie Toyne-Sewell / Jayne
Crook / Emma Barlow Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing access to medicines. Its mission is to deliver the right
medicine to the right patient at the right time.
The Group consists of five synergistic businesses focused in
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in
the management and supply of commercial medicines for clinical
trials.
The Group is also the trusted global leader in ethically
sourcing and supplying unlicensed medicines to hospital pharmacists
and physicians for patients with a high unmet need, through three
of its divisions: Idis Managed Access runs early access programs
for innovative new medicines. Idis Global Access and Link
Healthcare work directly with healthcare professionals to enable
compliant access to unlicensed medicines on a global basis and
niche essential licensed and generic medicines across Australasia,
Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights,
revitalises and markets its own portfolio of niche hospital
commercial products.
For more information, please visit www.clinigengroup.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLLFIAIILTLIR
(END) Dow Jones Newswires
October 19, 2016 03:00 ET (07:00 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024